The European Commission has approved Merck’s Januvia, a once-daily oral treatment for patients with type 2 diabetes. Januvia is the first medication in a new class of drugs known as dipeptidyl peptidase-4 inhibitors (DPP-4 inhibitors), which enhance the body’s own ability to lower blood sugar, to be adopted by the European Commission. Januvia is indicated in patients with type 2 diabetes to improve glycemic control in combination with metformin when diet and exercise plus metfor...